@thelancetoncol.bsky.social🆕Our October issue is live!
📊Articles: #ovariancancer, #breastcancer, #multiplemyeloma, #prostatecancer, #lungcancer
📉Trials: KEYLYNK-001, CHN HYPOPMRT, SYMPRO-Lung trial, OPTIMUM/MUKnine, STAMINA
🎨Cover: Cancer & the microbiome
Read here: thelancet.com/issue/S1470-...
@narrowit.bsky.socialIASO Bio Reports Early Responses in 10-Patient In Vivo CAR-T Study IASO Bio reported a 90% response rate in the first 10 evaluable multiple-myeloma patients treated with...
https://www.narrowit.com/news/iaso206-first-in-human-in-vivo-car-t-data-2026-09-27
#IasoBio #IASO206 #CART #MultipleMyeloma
@genesndiseases.bsky.socialTargeting #IRF4 could open a new path for #MultipleMyeloma therapy.
G1126 suppresses myeloma growth, reduces lenalidomide-resistant cells and enhances #chemotherapy response while sparing normal stem cells. @ECNUER
#GenesAndDiseases: doi.org/10.1016/j.ge...
@dustcircle.bsky.socialOne Man’s Perspective on His #MultipleMyeloma Journey
@jfadams1.bsky.social
@hematologyadvisor.bsky.socialIt's #BloodCancerAwarenessMonth!🩸
We recently interviewed experts C. Ola Landgren, MD, PhD and Kenneth Shain, MD, PhD to discuss the evolving treatment landscape and risk stratification methods for patients with high-risk smoldering #MultipleMyeloma
Read the full interview: https://bit.ly/47iDKcC
@uchicagocancer.bsky.socialA phase 1 trial co-led by Michael Bishop, MD, at the UChicago MedIcine, found that investigational BCMA-targeted CAR-T therapy anito-cel produced deep, durable responses in relapsed/refractory multiple myeloma. #CAR-TTherapy #MultipleMyeloma #BCMATargeted
https://ow.ly/agH950ZRalu
@hemehub.bsky.social🩸 Just over a week until the HemeHub Hematology Summit!
The countdown is on, and we’re getting ready to welcome hematology professionals to the Gaylord Texan Resort & Convention Center on October 3!
⮕ Register: hemehub.org/events/hemeh...
@hemehub.bsky.social🩸🔍 Today’s questions!
Swipe to see the answers and explanations!
#SmolderingMultipleMyeloma #SMM #MultipleMyeloma #Hematology #HemeOnc #Oncology #MedicalEducation #MedEd #HemeHub
@hemehub.bsky.social🩸 Facts about Smoldering Multiple Myeloma:
The immune microenvironment as a gatekeeper of progression, protective anti-SOX2 T-cell responses, early immune dysregulation, loss of stem-like TCF1/7+ T cells, and immune normalization following therapy.
@gmj-georgia.bsky.socialA phase 2 trial of teclistamab-based induction therapy in newly diagnosed multiple myeloma has been published in Nature Medicine with an aut… #Bispecificantibodies #Clinicaltrial #Immunotherapy #Multiplemyeloma #Teclistamab #Bispecificantibodies #Clinicaltrial #Immunotherapy #Multiplemyeloma #T…
@hemehub.bsky.social💭🎯 Today’s questions!
Swipe to see the answers and explanations!
#SmolderingMultipleMyeloma #SMM #MultipleMyeloma #Hematology #HemeOnc #Oncology #MedicalEducation #MedEd #ClinicalHematology #MRD #ASCT #StemCellTransplant #APOBEC #HemeHub
@hemehub.bsky.social🧬 Facts about Smoldering Multiple Myeloma:
Genomic MM vs. genomic MGUS, genomic drivers of progression, genomic biomarkers of non-progressors, the Genomic Scar Score (GSS), and the continuous genomic gradient from MGUS to SMM to MM.
#SMM #SmolderingMultipleMyeloma #MultipleMyeloma #Hematology
@4040rec.bsky.social@hemehub.bsky.social💡🚀 Today’s questions!
Swipe to see the answers and explanations!
#SMM #SmolderingMultipleMyeloma #MultipleMyeloma #Hematology #HemeOnc #Oncology #MedicalEducation #MedEd #ClinicalHematology #HemeHub
@hemehub.bsky.social🧬 Facts about Smoldering Multiple Myeloma:
Genomic drivers of progression, APOBEC and AID activity, genomic risk scoring, and MAF/MAFB translocations.
#SMM #SmolderingMultipleMyeloma #MultipleMyeloma #Hematology #HemeOnc #Oncology #MedicalEducation #MedEd #ClinicalHematology #HemeHub
@hemehub.bsky.socialHappening this Friday!
⮕ Register: hemehub.org/live-webinars
🌐 Learn more: hemehub.org
#SmolderingMyeloma #MultipleMyeloma #Myeloma #Hematology #HemOnc #Oncology #MedicalEducation #MedEd #HemeHub
@pharmaphorum.bsky.social#GSK has continued its drive to bulk up its #pipeline, taking global rights to a #Tcellengager (TCE) for #multiplemyeloma, developed by China's #ChimagenBiosciences, for up to $750 million.
@ihi-synthia.bsky.social🩸 This #BloodCancerAwarenessMonth, discover how SYNTHIA is exploring #SyntheticData to advance research in #DLBCL & #MultipleMyeloma — from clinical trials to treatment outcome prediction.
🔗 www.ihi-synthia.eu/use-cases
#BloodCancer #SYNTHIA #EUResearch #IHITransformingHealth #HorizonEU
@hemehub.bsky.social🌟🔎Today’s questions!
Swipe to see the answers and explanations!
#SMM #SmolderingMultipleMyeloma #MultipleMyeloma #Hematology #HemeOnc #Oncology #Immunology #MedicalEducation #MedEd #ClinicalHematology #HemeHub
